Short-term effects of fluvastatin therapy on plasma interleukin-10 levels in patients with chronic heart failure

Coronary Artery Disease

Volumn 19, Issue 7, 2008, Pages 513-519

  Tekin, Abdullah ^a   Sezgin, Nurzen ^a   Katircibaşi, Mahmut Tuna ^a   Tekin, Göknur ^a   Çölkesen, Yücel ^a   Sezgin, Alpay Turan ^a   Müderrisoǧlu, Haldun ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Cytokines; Fluvastatin; Heart failure; Interleukin 10; Statin

Indexed keywords

FLUINDOSTATIN; INTERLEUKIN 10; LIPID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CALCULATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; DOWN REGULATION; DRUG EFFECT; EXERCISE TEST; FEMALE; HEART FAILURE; HEART RATE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSTHORACIC ECHOCARDIOGRAPHY; VAGUS TONE;

AGED; CHRONIC DISEASE; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEART FAILURE; HEART RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; INTERLEUKIN-10; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 55749087511     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32830d27d2     Document Type: Article

References (54)

1. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3:315-322.
2. El-Menyar AA. Cytokines and myocardial dysfunction: state of the art. J Card Fail 2008; 14:61-74.
3. Anker SD, Von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004; 90:464-470.
4. Von Haehling S, Anker SD, Bassenge E. Statins and the role of nitric oxide in chronic heart failure. Heart Fail Rev 2003; 8:99-106.
5. Gong KZ, Song G, Spiers JP, Kelso EJ, Zhang ZG. Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches. Int J Clin Pract 2007; 61:611-621.
6. Sola S, Mir MQ, Rajagopalan S, Helmy T, Tandon N, Khan BV. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail 2005; 11:607-612.
7. Tousoulis D, Antoniades C, Vassiliadou C, Toutouza M, Pitsavos C, Tentolouris C, et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 2005; 7:1126-1132.
8. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Pitsavos C, Vlachopoulos C, et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 2005; 178:359-363.
9. Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 2003; 58:719-731.
10. Hasegawa H, Yamamoto R, Takano H, Mizukami M, Asawaka M, Nagai T, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 2003; 35:953-960.
11. Tekin G, Tekin A, Canatar T, Sipahi I, Unsal A, Katircibaşi T, et al. Simvastatin improves the attenuated heart rate recovery of type 2 diabetics. Pharmacol Res 2006; 54:442-446.
12. Katircibasi MT, Canatar T, Kocum HT, Erol T, Tekin G, Demircan S, et al. Decreased heart rate recovery in patients with heart failure: effect of fluvastatin therapy. Int Heart J 2005; 46:845-854.
13. Krum H, Ashton E, Reid C, Kalff V, Rogers J, Amarena J, et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007; 13:1-7.
14. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357:2248-2261.
15. Tsouli SG, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS. Should a statin be prescribed to every patient with heart failure? Heart Fail Rev 2007. doi: 10.1007/s10741-007-9041-2.
16. Raina A, Pickering T, Shimbo D. Statin use in heart failure: a cause for concern? Am Heart J 2006; 152:39-49.
17. Tousoulis D, Charakida M, Stefanadi E, Siasos G, Latsios G, Stefanadis C. Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol 2007; 115:144-150.
18. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 2002; 39:1567-1573.
19. Van der Harst P, Böhm M, Van Gilst WH, Van Veldhuisen DJ. The case for statin therapy in chronic heart failure. Clin Res Cardiol 2007. doi: 10.1007/ s00392-007-0610-0.
20. Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJ. Elevated soluble CD 14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997; 79:1426-1430.
21. Maack C, Kartes T, Kilter H, Schäfers HJ, Nickenig G, Bôhm M, et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1 -GTPase and represents a target for statin treatment Circulation 2003; 108:1567-1574.
22. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998; 31:1352-1356.
23. Indolfi C, Di Lorenzo E, Perrino C, Stingone AM, Curcio A, Torella D, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21 ras activation. Circulation 2002; 106:2118-2124.
24. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001; 104:317-324.
25. Ichiki T, Takeda K, Tokunou T, Iino N, Egashira K, Shimokawa H, et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001; 21:1896-1901.
26. ZacàV, Rastogi S, Imai M, Wang M, Sharov VG, Jiang A, et al. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 2007; 50:551-557.
27. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ. The HMG-CoA reductase inhibitor simvaslatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6:1004-1010.
28. Hanna IR Heeke B, Bush H, Brosius L, King-Hageman D, Dudley SC Jr, et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006; 3:881-886.
29. Vyas AK, Guo H, Moss AJ, Olshansky B, McNitt SA, Hall WJ, et al. MADIT-II Research Group. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006; 47:769-773.
30. Bleske BE, Nicklas JM, Bard RL, Brook RD, Gurbel PA, Bilden KP, et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 2006; 47:338-341.
31. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008; 51:415-426.
32. Li JJ, Li YS, Fang CH, Hui RT, Yang YJ, Cheng JL, et al. Effects of simvastatin within two weeks on anti-inflammatory cytokine interleukin 10 in patients with unstable angina. Heart 2006; 92:529-530.
33. Tsirpanlis G, Boufidou F, Manganas S, Chantzis K, Bleta A, Stamatelou K, et al. Treatment with fluvastatin rapidly modulates, via different pathways, and in dependence on the baseline level, inflammation in hemodialysis patients. Blood Purif 2004; 22:518-524.
34. Liakopoulos OJ, Dörge H, Schmitto JD, Nagorsnik U, Grabedünkel J, Schoendube FA. Effects of preoperative statin therapy on cytokines after cardiac surgery. Thorac Cardiovasc Surg 2006; 54:250-254.
35. Zhang J, Cheng X, Liao YH, Lu B, Yang Y, U B, et al. Simvastatin regulates myocardial cytokine expression and improves ventricular remodeling in rats after acute myocardial infarction. Cardiovasc Drugs Ther 2005; 19:13-21.
36. Chen CH, Lee RP, Wu WT, Liao KW, Hsu N, Hsu BG. Fluvastatin ameliorates endotoxin induced multiple organ failure in conscious rats. Resuscitation 2007; 74:166-174.
37. Nishio R, Matsumori A, Shioi T, Ishida H, Sasayama S. Treatment of experimental viral myocarditis with interieukin-10. Circulation 1999; 100:1102-1108.
38. Bolger AP, Sharma R, von Haehling S, Doehner W, Oliver B, Rauchhaus M, et al. Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure. Am J Cardiol 2002; 90:384-389.
39. Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreaseen AK, Ihlen H, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103:220-225.
40. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91:88-998.
41. Bolger AP, Anker SD. Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. Drugs 2000; 60:1245-1257.
42. Von Haehling S, Jankowska EA, Anker SD. Tumour necrosis factor-alpha and the failing heart: pathophysiology and therapeutic implications. Basic Res Cardiol 2004; 99:18-28.
43. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002; 86:123-130.
44. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Anti-TNF therapy against congestive heart failure investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 2003; 107:3133-3140.
45. Anker SD. Anti-tumour necrosis factor - a therapy in chronic heart failure - what went wrong? In: McMurray JJ, Pfeffer MA, editors. Heart failure updates. London: Martin Dunitz; 2003, pp. 201-213.
46. Khush KK, Waters DD. Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. J Card Fail 2006; 12:664-674.
47. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97:1129-1135.
48. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxymethylglutaryl coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103:113-118.
49. Bates K, Ruggeroli CE, Goldman S, Gaballa MA. Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction. Am J Physiol Heart Circ Physiol 2002; 283:H768-H775.
50. Trochu JN, Mital S, Zhang X, Xu X, Ochoa M, Liao JK, et al. Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res 2003; 60:250-258.
51. Floras JS. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol 1993; 4 (Suppl A): 72A-84A.
52. Imai K, Sato H, Hori M, Kusuoka H, Ozaki H, Yokoyama H, et al. Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure. J Am Coll Cardiol 1994; 24:1529-1535.
53. Anker SD, Clark AL, Winkler R, Zugck C, Cicoira M, Ponikowski P, et al. Statin use and survival in patients with chronic heart failure - results from two observational studies with 5200 patients. Int J Cardiol 2006; 112:234-242.
54. Krum H, Latini R, Maggioni AP, Anand I, Masson S, Carretta E, et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol 2007; 119:48-53.